# CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

> **NCT03408587** · PHASE1 · COMPLETED · sponsor: **Viralytics** · enrollment: 11 (actual)

## Conditions studied

- Uveal Melanoma
- Liver Metastases

## Interventions

- **BIOLOGICAL:** CVA21
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT03408587
- **Lead sponsor:** Viralytics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-29
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03408587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03408587, "CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03408587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*